{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:29:19Z","timestamp":1787236159452,"version":"build-2736575974"},"reference-count":44,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Serum fibroblast growth factor 23 (FGF23) levels and the renin-angiotensin-aldosterone system (RAAS) are elevated in chronic kidney disease (CKD) patients, and their association with left ventricular hypertrophy (LVH) has been reported. However, whether the FGF23 elevation is the cause or result of LVH remains unclear. At 10 weeks, male C57BL\/6J mice were divided into 4 groups: sham, CKD (5\/6 nephrectomy), LVH (transaortic constriction), and CKD\/LVH group. At 16 weeks, the mice were euthanized, and blood and urine, cardiac expressions of FGF23 and RAAS-related factors, and cardiac histological analyses were performed. Heart weight, serum FGF23 levels, and cardiac expression of FGF23 and RAAS-related factors, except for angiotensin-converting enzyme 2, were more increased in the CKD\/LVH group compared to the other groups. A significant correlation between LVH and cardiac expressions of FGF23 and RAAS-related factors was observed. Furthermore, there was a significantly close correlation of the cardiac expression of FGF23 with LVH and RAAS-related factors. The coexisting CKD and LVH increased serum and cardiac FGF23 and RAAS-related factors, and there was a significant correlation between them. A close correlation of cardiac, but not serum FGF23, with LVH and RAAS suggests that local FGF23 levels may be associated with LVH and RAAS activation.<\/jats:p>","DOI":"10.1210\/jendso\/bvab187","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T08:19:24Z","timestamp":1639383564000},"source":"Crossref","is-referenced-by-count":7,"title":["Changes of FGF23 and the Renin-Angiotensin-System in Male Mouse Models of Chronic Kidney Disease and Cardiac Hypertrophy"],"prefix":"10.1210","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5441-3623","authenticated-orcid":false,"given":"Kohei","family":"Okamoto","sequence":"first","affiliation":[{"name":"Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-1068","authenticated-orcid":false,"given":"Hideki","family":"Fujii","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Goto","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Kono","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Nishi","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"issue":"7","key":"2022021416533429200_CIT0001","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","article-title":"Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease","volume":"16","author":"Gutierrez","year":"2005","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"2022021416533429200_CIT0002","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11154-015-9318-z","article-title":"The PTH-vitamin D-FGF23 axis","volume":"16","author":"Blau","year":"2015","journal-title":"Rev Endocr Metab Disord."},{"issue":"19","key":"2022021416533429200_CIT0003","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Guti\u00e9rrez","year":"2009","journal-title":"Circulation."},{"issue":"11","key":"2022021416533429200_CIT0004","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest."},{"key":"2022021416533429200_CIT0005","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fendo.2018.00278","article-title":"Paracrine effects of FGF23 on the heart","volume":"9","author":"Leifheit-Nestler","year":"2018","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"1","key":"2022021416533429200_CIT0006","doi-asserted-by":"crossref","first-page":"11298","DOI":"10.1038\/s41598-017-10140-4","article-title":"Genetic ablation of Fgf23 or Klotho does not modulate experimental heart hypertrophy induced by pressure overload","volume":"7","author":"Slavic","year":"2017","journal-title":"Sci Rep."},{"issue":"2","key":"2022021416533429200_CIT0007","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/07435800.2016.1242604","article-title":"Patients with FGF23-related hypophosphatemic rickets\/osteomalacia do not present with left ventricular hypertrophy","volume":"42","author":"Takashi","year":"2017","journal-title":"Endocr Res."},{"key":"2022021416533429200_CIT0008","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3389\/fendo.2018.00351","article-title":"FGF23 in cardiovascular disease: innocent bystander or active mediator?","volume":"9","author":"St\u00f6hr","year":"2018","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"23","key":"2022021416533429200_CIT0009","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1007\/s00018-018-2885-x","article-title":"Crosstalk between FGF23- and angiotensin II-mediated Ca2+ signaling in pathological cardiac hypertrophy","volume":"75","author":"Mhatre","year":"2018","journal-title":"Cell Mol Life Sci."},{"issue":"5","key":"2022021416533429200_CIT0010","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/1753944716644583","article-title":"Aldosterone is associated with left ventricular hypertrophy in hemodialysis patients","volume":"10","author":"Feniman De Stefano","year":"2016","journal-title":"Ther Adv Cardiovasc Dis."},{"issue":"5","key":"2022021416533429200_CIT0011","doi-asserted-by":"crossref","first-page":"e0127839","DOI":"10.1371\/journal.pone.0127839","article-title":"The PTIP-associated histone methyltransferase complex prevents stress-induced maladaptive cardiac remodeling","volume":"10","author":"Stein","year":"2015","journal-title":"PLoS One."},{"issue":"6","key":"2022021416533429200_CIT0012","doi-asserted-by":"crossref","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol."},{"issue":"7","key":"2022021416533429200_CIT0013","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/j.1476-5381.2010.00873.x","article-title":"Guidelines for reporting experiments involving animals: the ARRIVE guidelines","volume":"160","author":"McGrath","year":"2010","journal-title":"Br J Pharmacol."},{"issue":"6","key":"2022021416533429200_CIT0014","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000313363","article-title":"Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease","volume":"31","author":"Siragy","year":"2010","journal-title":"Am J Nephrol."},{"issue":"6","key":"2022021416533429200_CIT0015","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1159\/000495393","article-title":"Phosphate homeostasis, inflammation and the regulation of FGF-23","volume":"43","author":"Lang","year":"2018","journal-title":"Kidney Blood Press Res."},{"issue":"3","key":"2022021416533429200_CIT0016","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.yjmcc.2008.06.008","article-title":"Transient activation of p38 MAP kinase and up-regulation of Pim-1 kinase in cardiac hypertrophy despite no activation of AMPK","volume":"45","author":"Lei","year":"2008","journal-title":"J Mol Cell Cardiol."},{"issue":"8","key":"2022021416533429200_CIT0017","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/CIRCULATIONAHA.112.090977","article-title":"Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling","volume":"126","author":"Zhang","year":"2012","journal-title":"Circulation."},{"issue":"6 Pt 2","key":"2022021416533429200_CIT0018","first-page":"H2468","article-title":"ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice","volume":"266","author":"Rockman","year":"1994","journal-title":"Am J Physiol."},{"key":"2022021416533429200_CIT0019","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10157-016-1363-8","article-title":"Mineral metabolism and cardiovascular disease in CKD","volume":"21","author":"Fujii","year":"2017","journal-title":"Clin Exp Nephrol."},{"issue":"11","key":"2022021416533429200_CIT0020","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/toxins11110647","article-title":"FGF23 and phosphate\u2013cardiovascular toxins in CKD","volume":"11","author":"Vogt","year":"2019","journal-title":"Toxins (Basel)."},{"issue":"23","key":"2022021416533429200_CIT0021","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1007\/s00018-019-03241-y","article-title":"\u03b1Klotho-FGF23 interactions and their role in kidney disease: a molecular insight","volume":"76","author":"Smith","year":"2019","journal-title":"Cell Mol Life Sci."},{"issue":"2","key":"2022021416533429200_CIT0022","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.atherosclerosis.2009.05.013","article-title":"Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population","volume":"207","author":"Mirza","year":"2009","journal-title":"Atherosclerosis."},{"issue":"6","key":"2022021416533429200_CIT0023","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","article-title":"Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy","volume":"22","author":"Grabner","year":"2015","journal-title":"Cell Metab."},{"issue":"1","key":"2022021416533429200_CIT0024","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.kint.2018.02.018","article-title":"Cardiac hypertrophy elevates serum levels of fibroblast growth factor 23","volume":"94","author":"Matsui","year":"2018","journal-title":"Kidney Int."},{"issue":"5","key":"2022021416533429200_CIT0025","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10157-018-1680-1","article-title":"Changes in serum and intracardiac fibroblast growth factor 23 during the progression of left ventricular hypertrophy in hypertensive model rats","volume":"23","author":"Fujii","year":"2019","journal-title":"Clin Exp Nephrol."},{"issue":"1","key":"2022021416533429200_CIT0026","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2215\/CJN.02110217","article-title":"FGF23 and left ventricular hypertrophy in children with CKD","volume":"13","author":"Mitsnefes","year":"2018","journal-title":"Clin J Am Soc Nephrol."},{"key":"2022021416533429200_CIT0027","doi-asserted-by":"crossref","first-page":"649921","DOI":"10.3389\/fphys.2021.649921","article-title":"Aldosterone is positively associated with circulating FGF23 levels in chronic kidney disease across four species, and may drive FGF23 secretion directly","volume":"12","author":"Radloff","year":"2021","journal-title":"Front Physiol."},{"issue":"18","key":"2022021416533429200_CIT0028","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.3390\/ijms20184634","article-title":"FGF23-mediated activation of local RAAS promotes cardiac hypertrophy and fibrosis","volume":"20","author":"B\u00f6ckmann","year":"2019","journal-title":"Int J Mol Sci."},{"issue":"1","key":"2022021416533429200_CIT0029","doi-asserted-by":"crossref","first-page":"12398","DOI":"10.1038\/s41598-018-30098-1","article-title":"Cardiovascular interactions between fibroblast growth factor-23 and angiotensin II","volume":"8","author":"Pi","year":"2018","journal-title":"Sci Rep."},{"issue":"2","key":"2022021416533429200_CIT0030","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.bbrc.2016.01.034","article-title":"Up-regulation of FGF23 release by aldosterone","volume":"470","author":"Zhang","year":"2016","journal-title":"Biochem Biophys Res Commun."},{"issue":"10","key":"2022021416533429200_CIT0031","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/ndt\/gfy006","article-title":"Fibroblast growth factor 23 is induced by an activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts","volume":"33","author":"Leifheit-Nestler","year":"2018","journal-title":"Nephrol Dial Transplant."},{"issue":"3","key":"2022021416533429200_CIT0032","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2022021416533429200_CIT0033","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1172\/JCI0215219","article-title":"1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system","volume":"110","author":"Li","year":"2002","journal-title":"J Clin Invest."},{"issue":"17","key":"2022021416533429200_CIT0034","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/CIRCULATIONAHA.111.032680","article-title":"Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy","volume":"124","author":"Chen","year":"2011","journal-title":"Circulation."},{"issue":"6","key":"2022021416533429200_CIT0035","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10557-015-6629-y","article-title":"The vitamin D receptor activator maxacalcitol provides cardioprotective effects in diabetes mellitus","volume":"29","author":"Fujii","year":"2015","journal-title":"Cardiovasc Drugs Ther."},{"issue":"2","key":"2022021416533429200_CIT0036","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-12-0341","article-title":"Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system","volume":"216","author":"Santos","year":"2013","journal-title":"J Endocrinol."},{"issue":"2","key":"2022021416533429200_CIT0037","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/MNH.0b013e3280123c0e","article-title":"The emerging role of angiotensin-converting enzyme-2 in the kidney","volume":"16","author":"Burns","year":"2007","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"6891","key":"2022021416533429200_CIT0038","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature."},{"issue":"1","key":"2022021416533429200_CIT0039","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/cvr\/cvr036","article-title":"Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47(phox) NADPH oxidase subunit","volume":"91","author":"Bodiga","year":"2011","journal-title":"Cardiovasc Res."},{"issue":"1","key":"2022021416533429200_CIT0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cardiores.2007.04.007","article-title":"Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice","volume":"75","author":"Oudit","year":"2007","journal-title":"Cardiovasc Res."},{"issue":"9","key":"2022021416533429200_CIT0041","doi-asserted-by":"crossref","first-page":"e44161","DOI":"10.1371\/journal.pone.0044161","article-title":"A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model","volume":"7","author":"Dai","year":"2012","journal-title":"PLoS One."},{"issue":"7","key":"2022021416533429200_CIT0042","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/ndt\/gfv025","article-title":"Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease","volume":"30","author":"Anguiano","year":"2015","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"2022021416533429200_CIT0043","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4239\/wjd.v7.i5.101","article-title":"Hyporeninemic hypoaldosteronism and diabetes mellitus: pathophysiology assumptions, clinical aspects and implications for management","volume":"7","author":"Sousa","year":"2016","journal-title":"World J Diabetes."},{"issue":"99","key":"2022021416533429200_CIT0044","first-page":"S55","article-title":"The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease","volume":"68","author":"Remuzzi","year":"2005","journal-title":"Kidney Int Suppl"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvab187\/41730930\/bvab187.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/6\/2\/bvab187\/42525382\/bvab187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/6\/2\/bvab187\/42525382\/bvab187.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T15:59:12Z","timestamp":1644854352000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvab187\/6460429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvab187","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,12,13]]},"article-number":"bvab187"}}